FGFR2 and neoplasm: In a series of 102 patients with BTCs, Arai et al. observed FGFR2 fusions (FGFR2-AHCYL1 or FGFR2-BICC1) in 13.6% of ICC (9/66 ICC), and that inhibition of FGFR2 impeded activation of MAPK pathway, which is responsible for uncontrolled tumor growth [28].